Arvinas (ARVN) Competitors $7.89 -0.01 (-0.11%) Closing price 07/3/2025 02:37 PM EasternExtended Trading$7.96 +0.07 (+0.87%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN vs. VCEL, RXRX, NAMS, DNLI, KNSA, APGE, CGON, AGIO, INDV, and IDYAShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Apogee Therapeutics (APGE), CG Oncology (CGON), Agios Pharmaceuticals (AGIO), Indivior (INDV), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. Its Competitors Vericel Recursion Pharmaceuticals NewAmsterdam Pharma Denali Therapeutics Kiniksa Pharmaceuticals International Apogee Therapeutics CG Oncology Agios Pharmaceuticals Indivior IDEAYA Biosciences Vericel (NASDAQ:VCEL) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Is VCEL or ARVN more profitable? Vericel has a net margin of 1.25% compared to Arvinas' net margin of -10.92%. Vericel's return on equity of 1.09% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets Vericel1.25% 1.09% 0.73% Arvinas -10.92%-7.74%-4.11% Does the media refer more to VCEL or ARVN? In the previous week, Vericel had 3 more articles in the media than Arvinas. MarketBeat recorded 3 mentions for Vericel and 0 mentions for Arvinas. Vericel's average media sentiment score of 1.54 beat Arvinas' score of 0.00 indicating that Vericel is being referred to more favorably in the media. Company Overall Sentiment Vericel Very Positive Arvinas Neutral Do analysts prefer VCEL or ARVN? Vericel currently has a consensus target price of $61.14, suggesting a potential upside of 46.33%. Arvinas has a consensus target price of $20.29, suggesting a potential upside of 157.12%. Given Arvinas' higher probable upside, analysts plainly believe Arvinas is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Arvinas 0 Sell rating(s) 10 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.55 Which has stronger earnings and valuation, VCEL or ARVN? Vericel has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$238.54M8.82$10.36M$0.031,392.83Arvinas$263.40M2.19-$198.90M-$0.66-11.96 Do institutionals & insiders believe in VCEL or ARVN? 95.2% of Arvinas shares are held by institutional investors. 5.2% of Vericel shares are held by insiders. Comparatively, 4.7% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, VCEL or ARVN? Vericel has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. SummaryVericel beats Arvinas on 11 of the 16 factors compared between the two stocks. Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$575.96M$2.88B$5.50B$9.01BDividend YieldN/A2.43%5.38%4.04%P/E Ratio-11.9621.5627.6020.30Price / Sales2.19172.94369.09103.84Price / CashN/A41.9536.6357.47Price / Book0.977.518.055.68Net Income-$198.90M-$55.05M$3.18B$249.13M7 Day Performance4.66%4.61%2.82%3.30%1 Month Performance13.54%4.89%3.70%5.20%1 Year Performance-66.98%5.84%35.41%21.38% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas3.1265 of 5 stars$7.89-0.1%$20.29+157.1%-67.0%$575.96M$263.40M-11.96420VCELVericel2.9359 of 5 stars$42.55+2.0%$61.14+43.7%-7.0%$2.14B$237.22M1,418.81300Positive NewsRXRXRecursion Pharmaceuticals2.1267 of 5 stars$5.06+0.6%$7.00+38.3%-28.4%$2.06B$58.84M-2.86400Analyst ForecastNAMSNewAmsterdam Pharma3.1274 of 5 stars$18.11-2.5%$42.89+136.8%-0.8%$2.03B$45.56M-9.634Positive NewsDNLIDenali Therapeutics4.6378 of 5 stars$13.99-0.8%$33.71+141.0%-31.0%$2.03BN/A-5.24430Positive NewsKNSAKiniksa Pharmaceuticals International3.5416 of 5 stars$27.67-1.3%$38.80+40.2%+45.8%$2.02B$423.24M-110.68220APGEApogee Therapeutics2.9257 of 5 stars$43.43+0.1%$94.60+117.8%+26.8%$2.00BN/A-12.0691News CoverageAnalyst ForecastInsider TradeHigh Trading VolumeCGONCG Oncology2.4061 of 5 stars$26.00+0.2%$58.67+125.6%-12.8%$1.98B$1.14M-17.2261AGIOAgios Pharmaceuticals4.1262 of 5 stars$33.26-0.6%$58.60+76.2%-14.2%$1.93B$36.50M2.96390Insider TradeINDVIndivior2.0984 of 5 stars$14.74+5.7%$17.00+15.3%+5.4%$1.92B$1.19B-47.551,051News CoverageHigh Trading VolumeIDYAIDEAYA Biosciences3.5461 of 5 stars$21.02-1.6%$53.42+154.1%-33.6%$1.84B$7M-5.8680 Related Companies and Tools Related Companies VCEL Competitors RXRX Competitors NAMS Competitors DNLI Competitors KNSA Competitors APGE Competitors CGON Competitors AGIO Competitors INDV Competitors IDYA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARVN) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
